Država: Kanada
Jezik: angleščina
Source: Health Canada
PHENYLEPHRINE HYDROCHLORIDE; BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; GUAIFENESIN
FOUNDATION CONSUMER BRANDS, LLC
R05FA02
OPIUM DERIVATIVES AND EXPECTORANTS
1MG; 0.4MG; 2MG; 20MG
SYRUP
PHENYLEPHRINE HYDROCHLORIDE 1MG; BROMPHENIRAMINE MALEATE 0.4MG; CODEINE PHOSPHATE 2MG; GUAIFENESIN 20MG
ORAL
100ML/1000ML
Narcotic (CDSA I)
ANTITUSSIVES
Active ingredient group (AIG) number: 0444284001; AHFS:
CANCELLED POST MARKET
2021-12-31
Page 1 of 29 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION N DIMETANE ® EXPECTORANT C Brompheniramine Maleate, Phenylephrine Hydrochloride, Guaifenesin and Codeine Phosphate Syrup 0.4 mg / 1 mg / 20 mg / 2 mg: per mL of syrup Antihistamine/Decongestant/Expectorant/Antitussive Foundation Consumer Brands LLC Pittsburgh, PA 15212, USA Date of Revision: January 28, 2021 Distributed by: Accuristix., Vaughan, ON L4H 3C5. Submission Control No: 247367 Page 2 of 29 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION .....................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS .................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................11 DOSAGE AND ADMINISTRATION ...........................................................................13 OVERDOSAGE ...............................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY ............................................................15 STORAGE AND STABILITY........................................................................................15 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................15 PART II: SCIENTIFIC INFORMATION ...............................................................................17 PHARMACEUTICAL INFORMATION ..........................................................................17 PART III: CONSUMER MEDICATION INFORMATIO Preberite celoten dokument